Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist

Table 7 Basic results. Cost-effectiveness analysis (Cost/QALY gained)^a

Years since initiation	PSM vs PC	PSM vs Hpc	PSM vs Hvp	PSM vs Dabi
1	12,289 €	4960 €	9120 €	Dominant
2	3519 €	Dominant	275 €	Dominant
3	770 €	Dominant	Dominant	Dominant
4	Dominant	Dominant	Dominant	Dominant
5	Dominant	Dominant	Dominant	Dominant
10	Dominant	Dominant	Dominant	Dominant
Lifetime	Dominant	Dominant	Dominant	Dominant

PSM Patient self-management; PCpc Primary care with portable coagulometer; Hpc Hospital with portable coagulometer; Hvp Hospital with venipuncture; Dabi Dabigatran
^aThe basic results are shown from the perspective of the health system. In the analysis from the social perspective, PSM was the dominant option in all cases except for the analysis at 1 year vs. PCpc, in which the iCER was 7352 € per QALY gained

ISSN: 1472-6963